Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06568783
PHASE2
Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
Sponsor: Farshad Moradi
View on ClinicalTrials.gov
Summary
This study proposes the use of a PET isotope, \[18F\]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory Dermatomyostitis.
Official title: Evaluation of Patients With Refractory Dermatomyositis Using [18F]- Fibroblast Activation Protein Inhibitor-74 (FAPI-74) PET/MRI Imaging
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2024-12
Completion Date
2028-10
Last Updated
2024-11-29
Healthy Volunteers
No
Conditions
Interventions
DRUG
[18F]-FAPI-74
\[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
Locations (1)
Stanford University
Stanford, California, United States